[1] WildRA,CarminaE,Diamanti-KandarakisE,DokrasA,et al.Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome aconsensus statement by the androgen excess and polycystic ovary syndrome(AE-PCOS) society x0007[J].ClinEndocrinol Metab,2010,95:2038~2049. [2] Zabuliene L,Tutkuviene J.Body composition and polycystic ovary syndrome[J].Medicina(Kaunas),2010,46(2):142~157. [3] 崔琳琳,陈子江.多囊卵巢综合征的临床分型及意义[J].中华妇产科杂志,2010,45(8):623~625. [4] 曹泽毅.中华妇产科学[M].北京:人民卫生出版社,1999.2118~2202. [5] Holzer H,Casper R,Tulandi T.A new era in ovulationinduction[J].Fertil Steril.2006,85(2):277~284. [6] Saha L,Kaur S,Saha PK.Pharmacothweapy of polycystic ovary syndrome an update[J].Fund Clin Pharmacol,2012,26(1):54~62. [7] 吴畏,冒韵东,王媁,等.不同内膜准备方案的1372个冻融胚胎移植周期的临床结局比较[J].南京医科大学学报(自然科学版)2010,30(10):1469~1474. [8] Azziz R.Controversy in clinica1 endocrinology:diagnosis of polycystic ovarian syndrome:the Rotterdam criteria are premature[J].Clin Endocrino1 Metab,2006,91(3):781~785. [9] Rong Li,Qiufang Zhang,Dongzi Yang,et al.Prevalence of polycystic ovary syndrome in women in China:A Large Community-Based Stud[J].Hum Reprod,2013,7:1~8. [10] Mitwally M , Casper R. The aromatase inhibitor, letrozole:a promising alternative for clomiphene citrate for induction of ovulation[J].Fertil Steril,2000,4(Suppl1): S35. [11] 耿蔷,郭遂群,全松,等.来曲唑促排卵对卵泡发育和子宫内膜影响的临床观察[J].实用医学杂志,2010,26(12):2209~2211. [12] 刘红梅,邢福祺,陈士岭.经阴道超声对体外受精-胚胎移植中子宫内膜容受性的评价[J].中国超声医学杂志,2005,21(11):861~863.
2017, Vol. 23 
冀公网安备13080202000677号